Coma

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

Retrieved on: 
Wednesday, April 3, 2024
ART, OXY, Annual report, Unitary state, Risk, Patient, Coma, Abdomen, Research, Meconium, Meconium aspiration syndrome, Human, Congenital diaphragmatic hernia, Intubation, Pharmaceutical industry

Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.

Key Points: 
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.
  • Inspira aims to explore how this potential additional application of the INSPIRA ART100 device to provide neonates with vital respiratory support could replace the currently used mechanical ventilators.
  • "Inspira is dedicated to pushing the boundaries of medical technology to save and improve lives," remarked Dagi Ben-Noon, CEO of Inspira Technologies.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Inspira™ Technologies Reports Full Year 2023 Financial Results

Retrieved on: 
Monday, March 25, 2024
ART, OXY, Research, Annual report, Unitary state, IIA, Intubation, Risk, Patent, Patient, Coma, S&M, Hospital, G&A, Coagulation, Insurance, D&O, Carbon, Human, Hemolysis, Marketing, FDA, Total, Food, Pharmaceutical industry

RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023.
  • With our ground-breaking technologies and products, we are not just looking at the horizon but actively shaping it, leveraging our proprietary technologies to make a meaningful impact."
  • Total operating expenses decreased to US$12,133,000 in of the year ended December 31, 2023, from US$14,893,000 in the same period of 2022.
  • As of December 31, 2023, financial liabilities at fair value totaled US$1,470,000 compared to US$26,000.

The American Diabetes Association and The Leapfrog Group Name 17 Hospitals as "Recognized Leaders in Caring for People Living with Diabetes"

Retrieved on: 
Wednesday, March 20, 2024
Hospital, Leapfrog, Diabetes, Patient, Coma, Hope, Doctor of Philosophy, Death, Meal, MD, Patient safety organization, Accident, Safety, Patient safety, Amputation, MGA, Hypoglycemia, Nursing

ARLINGTON, Va., March 20, 2024 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) and The Leapfrog Group announced the first hospitals to receive national designation as Recognized Leaders in Caring for People Living with Diabetes.

Key Points: 
  • ARLINGTON, Va., March 20, 2024 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) and The Leapfrog Group announced the first hospitals to receive national designation as Recognized Leaders in Caring for People Living with Diabetes.
  • The designation reflects a strong commitment to the safety and well-being of hospitalized people living with diabetes.
  • An estimated 30% of hospitalized people are living with diabetes , and more than 200,000 hospitalized people die every year from preventable safety problems.
  • Hospitals earning the Recognized Leader in Caring for People Living with Diabetes designation include:

Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Retrieved on: 
Monday, March 18, 2024
ART, OXY, Annual report, Unitary state, Risk, Patient, Coma, Research, Sale, Human, Ministry, Blood, Intubation, Medical device

"The enthusiastic support from local key-opinion leaders highlights the excitement surrounding our technology, setting the stage for its global journey.

Key Points: 
  • "The enthusiastic support from local key-opinion leaders highlights the excitement surrounding our technology, setting the stage for its global journey.
  • This method is expected to significantly reduce complications associated with traditional ventilation methods, shorten hospital stays and potentially save lives.
  • The INSPIRA™ ART (Gen 2) device is the culmination of extensive research and development efforts by the team at Inspira.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Retrieved on: 
Tuesday, March 12, 2024
ART, OXY, Annual report, Unitary state, Pressure, Risk, Patent, Inflammation, Patient, Coma, Carbon, Human, Bleeding, Hemolysis, Blood, Intubation, Medical device

The performance of the VORTX™, tested according to a regulatory guideline, was found to meet 100% of blood oxygenation requirements at various blood flow rates.

Key Points: 
  • The performance of the VORTX™, tested according to a regulatory guideline, was found to meet 100% of blood oxygenation requirements at various blood flow rates.
  • A significant leap forward in the development of safer, more effective medical devices designed to minimize patient risk and improve clinical outcomes.
  • The advanced experiments demonstrated the primary performance of the VORTX™ by collecting data on oxygenation, carbon dioxide removal, and pressures across the device during blood use.
  • This stands in stark contrast to membrane-based devices, which typically experience significant pressure drops, leading to potential damage to the patient's blood.

Jimmy ‘Barbecue’ Chérizier: the gangster behind the violence in Haiti who may have political aspirations of his own

Retrieved on: 
Wednesday, March 13, 2024
ABC News, Affection, Violence, Coma, Torture, Racism, Tonton Macoute, Prison, Crime, News, Survival, UN, Politics, Admiration, Brain, Drug

Over the past two weeks, Haiti’s powerful gangs have plunged a country already on life support into a coma.

Key Points: 
  • Over the past two weeks, Haiti’s powerful gangs have plunged a country already on life support into a coma.
  • He is an unelected leader, taking power after Haiti’s president was assassinated in 2021, and has presided over the country’s economic freefall.
  • But Chérizier has emerged from the armed insurrection as the most formidable leader in Haiti, and some suspect he may have political aspirations of his own.
  • Haiti’s history is replete with political leaders with very dubious pasts, and the country’s citizens are used to their violent machinations.
  • According to Chérizier, his brand of violent street politics is very much in tune with the need of the hour.

Political acumen

  • The current political instability in Haiti has largely been manufactured by Chérizier and the gangs he leads as a cleverly thought-out survival strategy.
  • So, on the one hand, Chérizier’s decision to stir up a political uprising can be seen as a planned strategy to scare off any external forces seeking to impose order.
  • Chérizier has used Henry’s unpopularity and controversial decision to deploy foreign police officers in the nation to drum up a nationwide violent fervour for political change.
  • With Henry now out of the political scene, the chance that Haitians will be forced to embrace such an outcome may not be far-fetched after all.


Amalendu Misra has received funding from
British Academy /
Nuffield Foundation

Where’s Kate? Speculation about the ‘missing’ princess is proof the Palace’s media playbook needs a re-write

Retrieved on: 
Wednesday, March 13, 2024
Online, Sandringham, Associated Press, Social media, Reuters, AFP, Breeding, Catherine, Princess of Wales, Easter, Coma, News, Incest, English, Duke, Pleasure, TMZ, Nausea, Vomiting, Pregnancy, Hysterectomy, Getty Images, Health, Princess, Hyperemesis gravidarum, Kensington Palace, Death, Practice, Divorce, Child, Comment, Buckingham Palace, Cancer

Social media have been awash with speculation about Catherine’s health and whereabouts.

Key Points: 
  • Social media have been awash with speculation about Catherine’s health and whereabouts.
  • As scrutiny reaches a fever pitch, we ask: why is the Palace’s typical media playbook no longer working?

Not so ‘unprecedented’

  • Anne Boleyn (circa 1501-1536), the second of six wives of Henry VIII, was executed after being found guilty of adultery, incest and treason.
  • The long-reigning Queen Victoria (1819-1901) was widely regarded as as a loyal wife and mother.
  • Yet she too became the target of gossip regarding her close friendship with Scottish servant John Brown after her husband, Prince Albert, died in 1861.

The Palace’s strategic communications

  • The royal family has gradually adjusted to new media and technologies, though not as quickly as the public might like.
  • On one hand, the Palace continues its age-old tradition of announcing major news on a noticeboard at the gates of Buckingham Palace.

Internet sleuthing and a manipulated image

  • There were also more serious claims that she was in a coma, or dead, or getting a divorce.
  • In the midst of this speculation, TMZ published a grainy photo of Catherine in the passenger seat of a car near Windsor Castle.
  • The public quickly realised the image was at best poorly photoshopped or at worst AI-generated.
  • The Associated Press, Getty Images, AFP and Reuters subsequently issued “kill notices” on the image, stating concerns it had been digitally manipulated.

Old media PR won’t work in a new media world

  • The situation with Catherine’s absence from public life exposes the limits of old media strategies in a “new media” world.
  • The Palace is used to being able to control media coverage through the royal rota, a select group of press outlets in the UK given access to royal events.
  • Yet the interest in Catherine’s health has prompted a number of statements to the press.
  • These old media strategies don’t seem to be working, with news outlets that are part of the royal rota reporting critically on the manipulated image.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.